Identifying and categorizing compounds that reduce corneal transforming growth factor beta induced protein levels: a scoping review.

Gabriella Guo Sciriha Salvatore CrisafulliJoseph Borg

Published in: Expert review of clinical pharmacology (2022)

expression and identified compounds that target these pathways. Compounds that inhibit DNA synthesis and function, increase elimination of TGFBIp or bind to mutant TGFBIp were also explored with the aim of highlighting promising compounds that can be used in future cost-effective drug-repurposing studies.

Keyphrases

transforming growth factor
epithelial mesenchymal transition
binding protein
single molecule
high glucose
small molecule
optical coherence tomography
current status
wound healing
nucleic acid
wild type